An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis

1996 ◽  
Vol 309 (3) ◽  
pp. 261-269 ◽  
Author(s):  
Cory M. Hogaboam ◽  
Milan J. Muller ◽  
Stephen M. Collins ◽  
Richard H. Hunt
Keyword(s):  
Receptor Antagonist ◽  
Rat Model ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Orally Active

Pharmacological Characterization of PABSA, an Orally Active and Highly Potent Endothelin-Receptor Antagonist

1999 ◽  
Vol 34 (1) ◽  
pp. 139-147 ◽  
Author(s):  
Takanori Iwasaki ◽  
Shin-ichi Mihara ◽  
Toshitake Shimamura ◽  
Masaru Kawakami ◽  
Yoko Hayasaki-Kajiwara ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Pharmacological Characterization ◽  
Orally Active

Orally Active Endothelin Receptor Antagonist BMS-182874 Suppresses Neointimal Development in Balloon-Injured Rat Carotid Arteries

1995 ◽  
Vol 26 (6) ◽  
pp. 908-915 ◽  
Author(s):  
Patricia Ferrer ◽  
Maria Valentine ◽  
Tonya Jenkins-West ◽  
Helen Weber ◽  
Nancy L. Goller ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Carotid Arteries ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor ◽  
Orally Active

Endothelin receptor antagonist bosentan attenuates leukocyte-endothelial adhesion and inflammation in a rat model of IBD

2000 ◽  
Vol 118 (4) ◽  
pp. A570
Author(s):  
Christoph Anthoni ◽  
Christian F. Krieglstein ◽  
Emile Rijcken ◽  
Mike G. Laukoetter ◽  
Rudolf Mennigen ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Rat Model ◽  
Endothelin Receptor Antagonist ◽  
Endothelin Receptor
Sign in / Sign up

Export Citation Format

Share Document